File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Potassium canrenoate, an aldosterone receptor antagonist, reduces isoprenaline-induced cardiac fibrosis in the rat

TitlePotassium canrenoate, an aldosterone receptor antagonist, reduces isoprenaline-induced cardiac fibrosis in the rat
Authors
Issue Date2004
PublisherAmerican Society for Pharmacology and Experimental Therapeutics. The Journal's web site is located at http://jpet.aspetjournals.org
Citation
Journal Of Pharmacology And Experimental Therapeutics, 2004, v. 309 n. 3, p. 1160-1166 How to Cite?
AbstractThe purpose of the present study was to determine whether the administration of an antagonist of aldosterone could prevent the fibrosis induced by an acute injection of isoprenaline. Male Wistar rats were submitted to one subcutaneous injection of isoprenaline (400 mg/kg) and were simultaneously treated with potassium canrenoate in drinking water (20 mg/kg/day) started 5 days before the injection of isoprenaline. Two months later, echocardiographic and hemodynamic measurements were performed. Then, the heart was prepared for morphometric histology and quantification of fibrosis in the left ventricle. Heart and left ventricular weights were increased significantly by isoprenaline. Potassium canrenoate attenuated this increase. The administration of isoprenaline increased significantly end diastolic diameter and end systolic volume compared with control. These changes were increased further with the addition of potassium canrenoate. In contrast, the fibrosis induced by isoprenaline was reduced significantly by potassium canrenoate at the three section levels. Potassium canrenoate attenuated the fibrosis but not the enhanced dilatation of the left ventricle induced by isoprenaline.
Persistent Identifierhttp://hdl.handle.net/10722/171334
ISSN
2015 Impact Factor: 3.76
2015 SCImago Journal Rankings: 1.847
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorBos, Ren_US
dc.contributor.authorMougenot, Nen_US
dc.contributor.authorMédiani, Oen_US
dc.contributor.authorVanhoutte, PMen_US
dc.contributor.authorLechat, Pen_US
dc.date.accessioned2012-10-30T06:13:27Z-
dc.date.available2012-10-30T06:13:27Z-
dc.date.issued2004en_US
dc.identifier.citationJournal Of Pharmacology And Experimental Therapeutics, 2004, v. 309 n. 3, p. 1160-1166en_US
dc.identifier.issn0022-3565en_US
dc.identifier.urihttp://hdl.handle.net/10722/171334-
dc.description.abstractThe purpose of the present study was to determine whether the administration of an antagonist of aldosterone could prevent the fibrosis induced by an acute injection of isoprenaline. Male Wistar rats were submitted to one subcutaneous injection of isoprenaline (400 mg/kg) and were simultaneously treated with potassium canrenoate in drinking water (20 mg/kg/day) started 5 days before the injection of isoprenaline. Two months later, echocardiographic and hemodynamic measurements were performed. Then, the heart was prepared for morphometric histology and quantification of fibrosis in the left ventricle. Heart and left ventricular weights were increased significantly by isoprenaline. Potassium canrenoate attenuated this increase. The administration of isoprenaline increased significantly end diastolic diameter and end systolic volume compared with control. These changes were increased further with the addition of potassium canrenoate. In contrast, the fibrosis induced by isoprenaline was reduced significantly by potassium canrenoate at the three section levels. Potassium canrenoate attenuated the fibrosis but not the enhanced dilatation of the left ventricle induced by isoprenaline.en_US
dc.languageengen_US
dc.publisherAmerican Society for Pharmacology and Experimental Therapeutics. The Journal's web site is located at http://jpet.aspetjournals.orgen_US
dc.relation.ispartofJournal of Pharmacology and Experimental Therapeuticsen_US
dc.subject.meshAldosterone Antagonists - Therapeutic Useen_US
dc.subject.meshAnimalsen_US
dc.subject.meshBlood Pressure - Drug Effectsen_US
dc.subject.meshCanrenoate Potassium - Therapeutic Useen_US
dc.subject.meshCardiomyopathies - Chemically Induced - Drug Therapy - Mortality - Physiopathologyen_US
dc.subject.meshDisease Models, Animalen_US
dc.subject.meshDose-Response Relationship, Drugen_US
dc.subject.meshFibrosis - Blood - Chemically Induced - Drug Therapy - Mortality - Physiopathologyen_US
dc.subject.meshHeart Rate - Drug Effectsen_US
dc.subject.meshIsoproterenolen_US
dc.subject.meshMaleen_US
dc.subject.meshNeurotransmitter Agents - Blooden_US
dc.subject.meshRatsen_US
dc.subject.meshRats, Wistaren_US
dc.subject.meshReceptors, Aldosterone - Antagonists & Inhibitorsen_US
dc.titlePotassium canrenoate, an aldosterone receptor antagonist, reduces isoprenaline-induced cardiac fibrosis in the raten_US
dc.typeArticleen_US
dc.identifier.emailVanhoutte, PM:vanhoutt@hku.hken_US
dc.identifier.authorityVanhoutte, PM=rp00238en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1124/jpet.103.063388en_US
dc.identifier.pmid14764658-
dc.identifier.scopuseid_2-s2.0-2442669009en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-2442669009&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume309en_US
dc.identifier.issue3en_US
dc.identifier.spage1160en_US
dc.identifier.epage1166en_US
dc.identifier.isiWOS:000221640900036-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridBos, R=7102085925en_US
dc.identifier.scopusauthoridMougenot, N=6602996596en_US
dc.identifier.scopusauthoridMédiani, O=6507974261en_US
dc.identifier.scopusauthoridVanhoutte, PM=7202304247en_US
dc.identifier.scopusauthoridLechat, P=7102784631en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats